UNSPSC 51312902: Etoloxamine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NEZ417265P. European Medicines Agency schedules Etoloxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07329MIG. Etoloxamine generally arises in the molecular formula C19H25NO.

UNSPSC 51312902 Etoloxamine is a Commodity code representing pharmaceutical products and related healthcare supplies procured by state and local governments. Recent solicitations show state and local agencies purchasing naloxone, generic pharmaceuticals, over-the-counter products, and drug deactivation systems through competitive bidding processes. The buying activity spans health departments, multistate cooperative purchasing alliances, and county public health agencies, with work ranging from one-time or recurring purchases of specific pharmaceutical inventories to longer-term framework agreements for pharmaceutical distribution across multiple state and local jurisdictions. The scope includes products that must meet FDA compliance, cGMP certification, and Drug Supply Chain Security Act requirements, with vendors expected to manage logistics, maintain appropriate insurance, and often coordinate delivery through established pharmaceutical wholesalers.

Recent opportunities demonstrate activity across Florida and the multistate procurement corridor. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 and a two-year initial term with one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products effective across participating state and local government facilities including Oregon, with proposals due March 26, 2026; the contract requires vendors to supply through three authorized wholesalers and comply with a 3 percent administrative fee and pricing structures weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued an exploratory Request for Information in April 2026 regarding direct-to-manufacturer prescription programs as part of its Therapeutic Pharmacy Initiative. Vendors should anticipate multi-jurisdictional cooperative purchasing frameworks, federal compliance overlays when FEMA funding is involved, and quarterly or ongoing delivery obligations to fixed locations.